RMD logo

ResMed Inc. Stock Price

NYSE:RMD Community·US$40.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 96 Fair Values set on narratives written by author

RMD Share Price Performance

US$278.59
46.30 (19.93%)
4.5% undervalued intrinsic discount
US$291.86
Fair Value
US$278.59
46.30 (19.93%)
3.8% undervalued intrinsic discount
US$289.71
Fair Value
Price US$278.59
AnalystConsensusTarget US$289.71

RMD Community Narratives

AnalystConsensusTarget·Updated
Fair Value US$291.86 4.5% undervalued intrinsic discount

Digital Health Platforms Will Expand Sleep Apnea Treatment Globally

2users have liked this narrative
0users have commented on this narrative
45users have followed this narrative

Recent RMD News & Updates

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Sep 06
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Jul 29
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed Inc. Key Details

US$5.1b

Revenue

US$2.1b

Cost of Revenue

US$3.1b

Gross Profit

US$1.7b

Other Expenses

US$1.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
9.60
Gross Margin
59.99%
Net Profit Margin
27.22%
Debt/Equity Ratio
11.2%

ResMed Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Outstanding track record with flawless balance sheet and pays a dividend.

0 Risks
3 Rewards

About RMD

Founded
1989
Employees
10600
CEO
Michael Farrell
WebsiteView website
www.resmed.co.in

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 8.5%
  • 1 Year: 17.7%
  • Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›